Skip to content
The Vancouver drug developer is licensing Swiss-based Roche the commercial rights to a chemical it calls ZW209, which is intended to fight certain cancers—especially in lungs—by triggering patients’ own immune systems to attack tumours. Zymeworks gets another US$40 million if the potential medication progresses through early clinical trials; if ZW209 becomes a commercial success, Roche could pay Zymeworks as much as US$718 million more. (The Logic)
Talking point: Zymeworks focuses on antibody-based treatments, working on both its own drugs and others in partnership with large pharmaceutical companies. ZW209 is early in the testing process, not yet having been tried in humans at all. But another Zymeworks-developed cancer drug called Ziihera has reached the market and could pay off with hundreds of millions of dollars from a commercial deal with Jazz Pharmaceuticals and BeOne Medicines.
Loading...
Thanks for sharing!
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseThis account has reached its share limit.
If you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseGift the full article!
You have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Most Popular This Week
In-depth, agenda-setting reporting
Great journalism delivered straight to your inbox.
Commentary
Carmichael: Being boxed in will help Canada focus on what matters
Briefing
Rio Tinto gets nearly $165M in additional federal funds for Quebec aluminum
U.S. to lift tariffs on some Canadian products crucial to Maine: Collins
Carney warns of tech dependence after Starlink disruptions in Ukraine
Best business newsletter in Canada
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
Exclusive events
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership in The Logic Council
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.
